Sarilumab (Kevzara®) in combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARD). Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.
|NCPE Rapid Review Process||Complete|
|Rapid review received||18/08/2017|
|Rapid review completed||04/10/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended at the submitted price.|
|Current Status||The company to not plan to submit a HTA.|
The company to not plan to submit a HTA dossier to the NCPE therefore the cost effectiveness of the technology cannot be proven.